Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Chief Medical Officer | May 08, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bicara Therapeutics Inc.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.58 · Expires 2036-05-08 | Direct | 85,000 |
Reported balance
After 2026-05-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 85,000 · Balance 85,000 F1: The shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 12, 2026 20:04 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $22.58 | $0.00 |
DisclosureSEC source: 0001628280-26-034087 · wk-form4_1778616247.xml · derivative · entry 1 Schelman William · CIK 0002132269 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2036-05-08 F1 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.